Formulary guidance and transparency from P&T to point of care


Reality Check on Multiple Sclerosis

Market access for MS treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.  

To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:

  • Payer Insights: Slight reductions in pharmacy benefit commercial and health exchange formulary restrictions
  • Class Trends: How neurologists now lead prescribings in the LTC segment and how specific MS prescribing is shifting
  • Key Findings: What makes coverage so complex in MS and why do dual-benefit products add both opportunity and risk?

What can pharma do to curb this trend and overcome these challenges?

Get the data behind this change and how it could impact your market access plans from MMIT's team.  Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.

Download the full Reality Check now.